日本国内では2020年9月までにジェネリック医薬品の使用割合を80％にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト＆ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。
深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析＆報告します。
Generics Bulletinでは以下のトピックをカバーしています。
Generics Bulletin: ジェネリック＆バイオシミラーニュース
12 Oct 2021
India leads the ways with the highest number of approved biosimilars.
Topic clinical-trials biosimilars
Generics Bulletin: ジェネリック＆バイオシミラーニュース
17 Sep 2021
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
14 Sep 2021
The Medicines Patent Pool has announced that the first shipments of dolutegravir under a fresh agreement covering upper-middle-income countries have reached Azerbaijan and Belarus.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By Akriti Seth 14 Sep 2021
India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
30 Jul 2021
Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By Akriti Seth 01 Jul 2021
Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By Akriti Seth 22 Jun 2021
After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By Akriti Seth 16 Jun 2021
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
11 Jun 2021
As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By David Wallace 08 Jun 2021
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By Akriti Seth 28 Apr 2021
As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
22 Apr 2021
Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By David Wallace 06 Apr 2021
Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
By Dean Rudge 18 Mar 2021
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
18 Jan 2021
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Generics Bulletin: ジ...
25 Oct 2021
Generics Bulletin: ジ...
22 Oct 2021
Generics Bulletin: ジ...
22 Oct 2021
Generics Bulletin: ジ...
22 Oct 2021
Generics Bulletin: ジ...
22 Oct 2021
Generics Bulletin: ジ...
22 Oct 2021
Generics Bulletin: ジ...
21 Oct 2021
Generics Bulletin: ジ...
21 Oct 2021
Generics Bulletin: ジ...
21 Oct 2021
Generics Bulletin: ジ...
21 Oct 2021
Generics Bulletin: ジ...
21 Oct 2021
Generics Bulletin: ジ...
20 Oct 2021
Generics Bulletin: ジ...
20 Oct 2021
Generics Bulletin: ジ...
19 Oct 2021
Generics Bulletin: ジ...
19 Oct 2021
UK
Aidan specializes in
22+ years of experience
UK
Duncan specializes in
21+ years of experience
UK
Andrea specializes in
17+ years of experience
無料トライアルお申込み
お問い合わせ先
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。
Eメール：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
